Schedule 13D ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2020-06-01

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,819,478
Percent of class
8.8000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001387131-20-005474
Form type
SC 13D/A
Filer
GSK plc
CIK
CIK 1131399
Filed
Jun 04, 2020
Reporting period
Jun 01, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub